Actelion talks to new party, reported to be Sanofi, as J&J drops bid

By Greg Roumeliotis and John Miller NEW YORK/ZURICH (Reuters) - Switzerland's Actelion Ltd confirmed it was in talks about a "strategic transaction", with a report that Sanofi had filled the gap left after U.S. healthcare group Johnson & Johnson ended its takeover bid. Actelion's shares were indicated 3.7 percent lower on Wednesday after The Wall Street Journal, citing people familiar with the matter, said France's Sanofi was now in talks with Europe's largest biotechnology drug marker. The